Metropolitan Life Insurance Company (MetLife)’s Passage Bio PASG Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-165	Closed	-$20.9K	–	2562
2021 Q4	$20.9K	Sell	165 -149	-47%	-$24.3K	﹤0.01%	2752
2021 Q3	$62.5K	Sell	314 -266	-46%	-$63.4K	﹤0.01%	2735
2021 Q2	$154K	Buy	580 +205	+55%	+$63.4K	﹤0.01%	2342
2021 Q1	$131K	Hold	375	–	–	﹤0.01%	2299
2020 Q4	$192K	Buy	375 +139	+59%	+$55.7K	﹤0.01%	1967
2020 Q3	$61.9K	Buy	236 +1	+0.4%	+$344	﹤0.01%	2437
2020 Q2	$129K	Buy	+235	New	+$106K	﹤0.01%	2101

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PASG Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 165 shares — an estimated $20.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PASG in Q2 2020 and held it in 7 quarters. The position peaked at $192K in Q4 2020. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 165 Passage Bio shares in Q1 2022, an estimated $20.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Passage Bio in Q2 2020 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Passage Bio position peaked at $192K in Q4 2020.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.